Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Antisense RNA Stories

2014-02-24 12:27:26

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM's Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California. In addition to providing an update on its flagship program targeting transthyretin (TTR)-mediated amyloidosis, Arcturus will present data for its proprietary LUNAR(TM) delivery...

2014-01-30 08:30:19

- Arcturus proprietary LUNAR(TM) delivery technology demonstrates exceptional potency in vivo, ED(50) of 0.020 mg/kg SAN DIEGO, Jan. 30, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc. today announced it will present a poster at the Keystone Symposia Conference on RNA Silencing held January 31- February 5, 2014 in Seattle, Washington. The Arcturus poster titled "Design of a Novel, Potent, and Safe RNA Therapeutic Platform Utilizing LUNAR(TM) Delivery Technology" (poster...

2013-03-22 16:23:38

CARLSBAD, Calif., March 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO(TM) (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia...

2013-01-29 20:21:26

CARLSBAD, Calif., Jan. 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will conduct a conference call and webcast to provide an update on the U.S. Food and Drug Administration (FDA) approval of the marketing of KYNAMRO(TM) (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH). CONFERENCE CALL At 09:30 a.m. Eastern Time, Wednesday, January 30, 2013, Isis will conduct a live audio webcast and conference call....

2013-01-08 20:21:26

WAYNE, Pa., Jan. 8, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/isis) announces that a class action lawsuit has been filed in the United States District Court for United States District Court for the Southern District of California on behalf of all persons or entities that purchased the stock of Isis Pharmaceuticals, Inc. ("Isis Pharmaceuticals" or the "Company") (NASDAQ: ISIS) from March 29, 2012 through October 15, 2012, inclusive (the "Class Period")....

2013-01-03 20:20:40

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the Southern District of California on behalf of a class (the "Class") of purchasers of Isis Pharmaceuticals, Inc. ("Isis" or the "Company") (NASDAQ: ISIS) securities between March 29, 2012 and October 15, 2012 inclusive (the "Class Period"). (Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO) Isis is the leading company in...

2012-08-30 06:24:31

CARLSBAD, Calif., Aug. 30, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the publication of two papers in the journal Cell demonstrating that single-stranded short interfering RNA (ss-siRNA) molecules distributed broadly, activated the RNA interference (RNAi) pathway and reduced expression of targeted genes in animal models. The RNAi pathway is a mechanism that can be used to inhibit expression of genes. The RNAi pathway has typically been engaged by short...

2012-02-29 06:00:00

CARLSBAD, Calif., Feb. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2011 financial results and reviewed the highlights of the year. Isis finished 2011 with a pro forma net operating loss (NOL) of $61.3 million compared to a pro forma NOL of $36.2 million for 2010. The Company finished 2011 with nearly $344 million in cash. On a GAAP basis, Isis reported a loss from operations of $18.6 million and $71.1 million for the three and twelve months ended...

2012-01-05 09:47:00

CARLSBAD, Calif., Jan. 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast: What: Isis Pharmaceuticals' R&D Webcast Presentation When: Thursday, January 05, 2012 at 9:00 a.m. PT / 12:00 p.m. ET Where: www.isispharm.com How: Live on the Internet. Simply log on to our Web site listed above. If you are...

2011-12-22 07:17:39

Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism. Known as Angelman syndrome, or AS, its most characteristic feature is the absence or near absence of speech throughout the person's life. Occurring in one in 15,000 live births, other AS characteristics include intellectual and developmental delay, severe intellectual disability, seizures, sleep...